
According to data from Benzinga Pro, during Q4, Catalyst Biosciences's (NASDAQ:CBIO) reported sales totaled $2.44 million. Despite a 19.45% increase in earnings, the company posted a loss of $20.33 million. Catalyst Biosciences collected $2.30 million in revenue during Q3, but reported earnings showed a $25.24 million loss.